Micafungine Viatris

Micafungin, the active ingredient in Micafungine, is an echinocandin presented as an intravenous formulation for infusion use. It treats serious fungal infections such as invasive candidiasis, esophageal candidiasis, Candida peritonitis and febrile neutropenia in immunocompromised patients.

GNH USA supplies Micafungine as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres and pharmacies worldwide.

Micafungine is an echinocandin antifungal used to treat systemic and mucosal Candida infections.

- Invasive candidiasis: effective treatment of bloodstream and deep‑tissue Candida infections. - Esophageal candidiasis: resolves esophageal lesions caused by Candida species. - Candida peritonitis: controls intra‑abdominal Candida infection. - Febrile neutropenia: provides empirical antifungal coverage in neutropenic patients at risk of invasive fungal disease.

Micafungine may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Fever: transient temperature elevation during infusion. - Headache: mild to moderate headache reported. - Nausea: occasional gastrointestinal upset. - Infusion‑related reactions: flushing, chills, or rigors. - Elevated liver enzymes: transient increase in ALT/AST. - Rash: mild skin erythema.

Serious or Rare Side Effects: - Hepatic failure: severe liver injury requiring monitoring. - Anaphylaxis: acute hypersensitivity reaction. - Severe hypotension: marked blood pressure drop during infusion. - Renal impairment: acute kidney injury in susceptible patients. - Stevens‑Johnson syndrome: rare severe skin reaction. - Fatal outcomes: extremely rare but reported in critically ill patients.

When using Micafungine, clinicians should observe several safety measures.

- Renal function: assess baseline renal status and monitor during therapy. - Hepatic function: check liver enzymes before and periodically during treatment. - Drug interactions: review concomitant medications for potential CYP interactions. - Pregnancy: prescribe only if potential benefit justifies potential risk to the fetus. - Storage: Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Micafungine can interact with other drugs, requiring careful management.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin): may markedly reduce micafungin exposure. - Co‑administration with other echinocandins: increased risk of toxicity. - Concurrent use with potent CYP3A4 inhibitors (e.g., ketoconazole): may elevate micafungin levels.

Moderate Interactions (Monitor Closely): - Azole antifungals (e.g., fluconazole): may increase micafungin concentrations. - Immunosuppressants (e.g., tacrolimus, cyclosporine): may require dose adjustments. - Statins (e.g., simvastatin): monitor for myopathy or rhabdomyysis.